- Record second quarter and first half revenue s of EUR 14.3 million (USD 15 .5 million) and EUR 29.1 million (USD 31.5 million), respectively - - Total HIFU Q 2 2023 year - over - year revenue growth of 63. 6 % - - S trong Q 2 2023 year-over-year U.S.

  University of Miami Sylvester Comprehensive Cancer Center , a Long-Time EDAP Ablatherm® User, to Upgrade to the Most Advanced HIFU Technology for the Treatment of Prostate Disease Focal One Successfully Launched with Several Patients Treated to Date LYON, France , January 29, 2020 – EDAP TMS SA

Increasing Adoption of HIFU Focal in Leading French Robotic Prostate Cancer Centers

HIFU Focal Therapy Showcased at 66th German Society of Urology Congress

Montreal Jewish General Hospital, Canada, Purchases Focal One HIFU Two Months After Health Canada Clearance

100% Cancer Specific Survival, 94% Continence Preservation and 80% Potency Preservation

Strong Recognition of EDAP's HIFU Technology by France's Health Authorities

LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer.

Allows for market launch of the only micro - ultrasound platform for precision prostate biopsies LYON, France, April 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today provided a regulatory and clinical update.

Company preliminarily reports nine Focal One Placements in the U.S. , including seven sales LYON, France, January 5, 2023 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company experienced robust demand for its Focal One